IRT systems for clinical trials — Interactive Response Technology systems — are software platforms that automate participant randomization and investigational product supply management throughout a clinical study. They replace manual, paper-based processes with validated, auditable digital workflows that meet the data integrity expectations of regulatory agencies including the FDA and EMA.

The acronym IRT originates from Interactive Response Technology, a term that encompasses both the historical telephone-based systems that preceded current software platforms and the web-based RTSM (Randomization and Trial Supply Management) systems used today.

Core Functions of IRT Systems

IRT systems for clinical trials perform two foundational functions that are operationally inseparable in practice.

Randomization. The randomization engine assigns enrolled participants to treatment arms according to the statistical design specified in the trial protocol. This includes the randomization method — block, stratified, minimization, or adaptive — and the application of any stratification factors such as site, age group, or disease severity. The IRT system applies these rules automatically and consistently, eliminating the human error risk inherent in manual assignment.

Trial supply management. IRT systems track investigational product inventory at every level of the supply chain — from global depots through regional distribution points to individual investigational sites. They record every dispensing event, manage drug expiry by lot, trigger resupply orders when site inventory falls below defined thresholds, and document drug returns and destruction.

Why Manual Processes Are Insufficient

In a simple, small-scale trial, manual randomization using sealed envelopes and spreadsheet-based inventory tracking may appear manageable. The limitations of this approach become apparent as trial complexity increases.

Multi-site studies with dozens or hundreds of sites generating simultaneous enrollment activity cannot be reliably managed through manual processes without unacceptable risk of randomization error and supply inconsistency. Adaptive designs, where the randomization algorithm may need to change based on interim data, require computational precision that manual systems cannot provide. IRT systems for clinical trials are designed specifically for this level of operational complexity.

Regulatory Compliance Requirements

Regulatory agencies that review data from randomized controlled trials expect IRT systems to meet defined standards for electronic records, audit trails, and validation. In the United States, 21 CFR Part 11 establishes requirements for electronic records and electronic signatures in FDA-regulated environments. In Europe, Annex 11 of the EU GMP guidelines governs computerized systems used in clinical research.

An IRT system used in a pivotal trial must have complete validation documentation — installation qualification, operational qualification, and performance qualification records — and must maintain a complete audit trail of every system event. Regulatory inspectors reviewing clinical trial data routinely examine IRT audit trails as part of their assessment of data integrity.

Integration with the Broader Clinical Technology Stack

IRT systems for clinical trials do not operate in isolation. In a well-structured clinical trial technology environment, the IRT system exchanges data with the Electronic Data Capture (EDC) system, the Clinical Trial Management System (CTMS), and any external supply chain management platforms. This data exchange reduces manual transcription, eliminates reconciliation gaps between systems, and provides a more complete real-time view of trial status.

The RTSM platform for clinical trials represents the current integrated approach to IRT functionality, combining randomization and supply management within a single validated system.

Practical Considerations for IRT Selection

Sponsors selecting IRT systems for clinical trials should evaluate platform capabilities against specific protocol requirements before committing to a system. Key considerations include the randomization designs the platform supports, the supply management algorithms available, integration capabilities with existing systems, implementation timeline, validation documentation quality, and the vendor’s track record supporting regulatory submissions and inspections.